Shots:

• The ongoing OLE of ALITHIOS study involves assessing Kesimpta in 1-703 patients with MS for ~5 yrs which showed mean IgG levels remained unchanged @ 3.5 yrs & mean IgM levels remained within the reference range with no increased risk of infections
• Additionally- the results were consistent with P- III ASCLEPIOS trials data which showed a low incidence of infections & no association was identified b/w decreased Ig levels & risk of serious infections & was a well-tolerated treatment option for patients with RMS
• Kesimpta is a targeted B-cell therapy while results are presented at EAN 2021 with other wide-ranging data to understand the impact of the immune response toward vaccinations

  Ref: Novartis | Image: Novartis